Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly

Clinical Endocrinology

Volumn 69, Issue 2, 2008, Pages 279-284

  Delaroudis, Sideris P ^b   Efstathiadou, Zoe A ^a,b   Koukoulis, George N ^c   Kita, Marina D ^b   Farmakiotis, Dimitrios ^b   Dara, Ourania G ^b   Goulis, Dimitrios G ^b   Makedou, Areti ^d   Makris, Pantelis ^d   Slavakis, Aris ^b   Avramides, Avraam I ^b  

^a Hippokration General Hospital of Thessaloniki ^*  (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTREOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ACROMEGALY; ADULT; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART HEMODYNAMICS; HEART MUSCLE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; METABOLIC REGULATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ACROMEGALY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; FEMALE; HEMODYNAMICS; HORMONE ANTAGONISTS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OCTREOTIDE; RISK FACTORS; SOMATOSTATIN; TREATMENT FAILURE;

EID: 47549085040     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03181.x     Document Type: Article

References (34)

1. Orme, S.M., McNally, R.J.Q., Cartwright, R.A. Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism, 83, 2730 2734.
2. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95 102.
3. Colao, A.M., Ferone, D., Marzullo, P. Lombardi, G. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102 152.
4. Saccà, L., Cittadini, A. Fazio, S. (1994) Growth hormone and the heart. Endocrine Reviews, 15, 555 573.
5. Colao, A., Marzullo, P., Di Somma, C. Lombardi, G. (2001) Growth hormone and the heart. Clinical Endocrinology, 54, 137 154.
6. Jaffrain-Rea, M.L., Moroni, C., Baldelli, R., Battista, C., Maffei, P., Terzolo, M., Correra, M., Ghiggi, M.R., Ferretti, E., Angeli, A., Sicolo, N., Trischitta, V., Liuzzi, A., Cassone, R. Tamburrano, G. (2001) Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology, 54, 189 195.
7. Oscarsson, J., Wiklund, O., Jakobsson, K.E., Petruson, B. Bengtsson, B.A. (1994) Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clinical Endocrinology, 41, 603 608.
8. Wildbrett, J., Hanefeld, M., Fucker, K., Pinzer, T., Bergmann, S., Siegert, G. Breidert, M. (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Experimental and Clinical Endocrinology and Diabetes, 105, 331 335.
9. Inukai, T., Fujiwara, Y., Tayama, K., Aso, Y. Takemura, Y. (1996) Clinical significance of measurement of urinary and serum thrombomodulin in patients with non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice, 33, 99 104.
10. McLaren, M., Elhadd, T.A., Greene, S.A. Belch, J.J.F. (1999) Elevated thrombomodulin and vascular endothelial growth factor in juvenile type-1 diabetic patients. Clinical and Applied Thrombosis/Hemostasis, 5, 21 24.
11. Merola, B., Cittadini, A., Colao, A., Ferone, D., Fazio, S., Sabatini, D., Biondi, B., Sacca, L. Lombardi, G. (1993) Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. Journal of Clinical Endocrinology and Metabolism, 77, 790 793.
12. Minniti, G., Moroni, C., Jaffrain-Rea, M.L., Esposito, V., Santoro, A., Affricano, C., Cantore, G., Tamburrano, G. Cassone, R. (2001) Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clinical Endocrinology, 55, 307 334.
13. Maldonado Castro, G.F., Escobar-Morreale, H.F., Ortega, H., Gomez-Coronado, D., Balsa Barro, J.A., Varela, C. Lasuncion, M.A. (2000) Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clinical Endocrinology, 53, 313 319.
14. Damjanovic, S.S., Neskovic, A.N., Petakov, M.S., Popovic, V., Macut, D., Vucojevic, P. Joksimovic, M.M. (2005) Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clinical Endocrinology, 62, 410 417.
15. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., Von Werder, K. Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529.
16. Melmed, S., Casanueva, F.F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Vance, M.L., Von Werder, K., Wass, J. Giustina, A. (2002) Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism, 87, 4054 4058.
17. Matsuda, M. DeFronzo, R.A. (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care, 22, 1462 1470.
18. Lie, J.T. Grossman, S.J. (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. American Heart Journal, 100, 41 52.
19. Minniti, G., Jaffrain-Rea, M.L., Moroni, C., Baldelli, R., Ferretti, E., Cassone, R., Gulino, A. Tamburrano, G. (1998) Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clinical Endocrinology, 49, 101 106.
20. Colao, A., Baldelli, R., Marzullo, P., Ferretti, E., Ferone, D., Gargiulo, P., Petretta, M., Tamburrano, G., Lombardi, G. Liuzzi, A. (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 85, 193 199.
21. McGuffin, W.L. Jr., Sherman, B.M., Roth, F., Gorden, P., Kahn, C.R., Roberts, W.C. Frommer, P.L. (1974) Acromegaly and cardiovascular disorders. A prospective study. Annals of Internal Medicine, 81, 11 18.
22. Wright, A.D., Hill, D.M., Lowy, C. Russell-Fraser, T. (1970) Mortality in acromegaly. Quarterly Journal of Medicine, 153, 1 16.
23. Bengtsson, B., Eden, S., Ernest, I., Oden, A. Sjogren, B. (1988) Epidemiology and long-term survival in acromegaly. Acta Medica Scandinavica, 223, 327 335.
24. Shepphard, M.C. (2003) Primary medical therapy in acromegaly. Clinical Endocrinology, 58, 387 399.
25. Clayton, R.N. (1997) New developments in the management of acromegaly. Should we achieve an absolute biochemical cure? Journal of Endocrinology, 155 (Suppl. 1S 23 29.
26. Lissett, C.A., Peacey, S.R., Laing, I., Tetlow, L., Davis, J.R. Shalet, S.M. (1998) The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical Endocrinology, 49, 653 657.
27. Nomikos, P., Buchfelder, M. Fahlbusch, R. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology, 152, 379 387.
28. Landin-Wilhelmsen, K., Tengborn, L., Wilhelmsen, L. Bengtsson, B.Å. (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clinical Endocrinology, 46, 69 74.
29. Sesmilo, G., Fairfield, W.P., Katznelson, L., Pulaski, K., Freda, P.U., Bonert, V., Dimaraki, E., Stavrou, S., Vance, M.L., Hayden, D. Klibanski, A. (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. Journal of Clinical Endocrinology and Metabolism, 87, 1692 1699.
30. Otsuki, M., Kasayama, S., Yamamoto, H., Saito, H., Sumitani, S., Kouhara, H., Saitoh, Y., Ohnishi, T. Arita, N. (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clinical Endocrinology, 54, 791 796.
31. Colao, A., Spiezia, S., Cerbone, G., Pivanello, R., Marzullo, P., Ferone, D., Di Somma, D., Assanti, A.P. Lombardi, G. (2001) Increased intima-media thickness by B-M mode echo-Doppler ultrasonography in acromegaly. Clinical Endocrinology, 54, 515 524.
32. Pfeifer, M., Verhovec, R., Zizek, B., Prezelj, J., Poredos, P. Clayton, R.N. (1999) Growth hormone treatment (GH) reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 453 457.
33. Evans, L.M., Davies, J.S., Anderson, R.A., Ellis, G.R., Jackson, S.K., Lewis, M.J., Frenneaux, M.P., Rees, A. Scanlon, M.F. (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. European Journal of Endocrinology, 142, 254 262.
34. Holdaway, I.M., Rajasoorya, R.C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674.